Duration of Illness and Response to Pimavanserin in Parkinson’s Disease Psychosis: Post-Hoc Analysis of Clinical Trial Data
Objective: To examine individual responses to pimavanserin in patients with Parkinson’s disease psychosis (PDP) initiating treatment <6 vs ≥6 months and <12 vs ≥12 months…Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion Foslevodopa/Foscarbidopa Therapy
Objective: This study aims to identify clinical predictors of continuous subcutaneous infusion (CSCI)-induced psychosis to understand its potential mechanisms and evaluate predictive measures for its…Demographic Features, QTc Interval and Psychosis in Military Veterans with Parkinson’s disease (PD)
Objective: To compare certain key demographic features and QTc intervals in groups of PD military Veterans with and without psychosis. Background: Psychosis is a disabling…Refining the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS): Cognitive Interview Results from an International Study
Objective: To assess the face and content validity of the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS), a new under-developing Clinical…Trends in U.S. Drug Use Among Hospitalized Parkinson’s Patients Experiencing Delirium
Objective: To examine drug use trends among hospitalized Parkinson’s disease (PD) patients in the U.S. and to assess the association between PD medications and delirium.…Predicting the Cognitive-Psychiatric Phenotype of Parkinson’s Disease
Objective: Predict PD patient’s clinical scores from brain activity. Inform on which assessments capture true changes in cortical dynamics caused by PD and explain those…Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies
Objective: To summarize the sleep and sedation-related safety and tolerability of pimavanserin for the treatment of Parkinson’s disease psychosis (PDP). Background: Pimavanserin, a 5-HT2A receptor…Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.
Objective: To describe the clinical and demographic characteristics of patients with PDP and their relationship with the use of DAs. Background: Parkinson’s Disease Psychosis (PDP)…Diagnostic Challenges in Functional Neurological Disorder: Convergent Psychogenic Non-Epileptic Seizures and Psychosis
Objective: To dissect the diagnostic challenges in distinguishing Functional Neurological Disorder (FND) coexisting with psychosis, highlighting the imperative for comprehensive and nuanced neuro-psychiatric assessment. Background:…Conceptualization of the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS) prototype.
Objective: To outline the process of conceptualizing the prototype for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Approximately…
- 1
- 2
- 3
- …
- 13
- Next Page »